Solutions
Advisory Services
Clinical Development
- Generics Development
- Clinical Operations
- Clinical Data Sciences
- Medical and Safety Services
- RWD & RWE Services
Post Marketing
- Safety Services
- Post marketing Studies
- Regulatory Affairs
Five Mistakes Companies Make During eCTD 4.0 Implementation And How to Avoid Them The regulatory landscape is entering one of its most significant periods of transformation since the adoption of electronic submissions. As health authorities worldwide prepare for eCTD 4.0 implementation, pharmaceutical, biotechnology and medical device companies fac...
Meet Navitas Life Sciences at Pharmacovigilance India 2026 As the pharmaceutical industry embraces artificial intelligence, real-world evidence and increasingly complex global regulations, Pharmacovigilance India 2026 promises to be one of the most influential forums for shaping the future of drug safety. Bringing together regulators, pharmaceutica...
Drug development begins with one fundamental question: How does the body handle a drug and how does the drug affect the body?The answer comes from pharmacokinetic (PK) and pharmacodynamic (PD) studies, which form the backbone of early clinical development. Whether developing a new molecular entity, a generic drug or a biosimilar, sponsors rely on p...
Boutique by Design. Outcome-focused by Model. As clinical trials become increasingly complex, sponsors need more than functional support, they need expert clinical data science expertise that transforms data into confident decisions. The clinical research industry is entering a new phase of complexity. Global clinical trials are becoming larger, mo...
How biotech companies can identify the right CRO partner to accelerate patient recruitment, improve trial quality, reduce operational burden and deliver regulatory-ready data. The way clinical trials are conducted has changed dramatically over the last five years. What began as a necessity during the COVID-19 pandemic has evolved into a strategic a...
Scientific breakthroughs in oncology, rare diseases, cell and gene therapies, immunology and precision medicine are increasingly being driven by agile and innovative biotech companies rather than pharmaceutical giants alone. Yet many emerging organizations face a familiar challenge: how can they achieve the operational sophistication of large pharm...
25 Years in 25 Voices of Peer Leadership For 25 years, the forums and peer networks powered by Navitas Life Sciences have brought together pharmaceutical, biotech, pharmacovigilance and regulatory leaders to exchange ideas, solve complex challenges and support the growth of the life sciences industry. In an industry defined by rapid transformation,...
How Foundations, Biotech and Pharma Organizations Can Accelerate Parkinson’s Studies with the Right Clinical Research Partner Parkinson’s disease research is entering a pivotal era. As scientific understanding of neurodegenerative disorders expands, organizations are moving beyond symptom management toward disease modification, precis...
How integrated clinical, regulatory, pharmacovigilance and data science ecosystems are accelerating global development programs Insights ahead of the 2026 DIA China Annual Meeting Global drug development is becoming increasingly complex and sponsors need to manage changing regulatory requirements, decentralized trial models, increasing operational ...
Selecting the right clinical research organization (CRO) can determine the success or failure of a biotech company’s clinical program. With increasing complexity in clinical trials, regulatory demands and cost pressures, choosing the right CRO partner is more critical than ever. Yet many biotech companies continue to make avoidable mistakes ...